[go: up one dir, main page]

MX2023015152A - Anticuerpos anti-cd20 canino. - Google Patents

Anticuerpos anti-cd20 canino.

Info

Publication number
MX2023015152A
MX2023015152A MX2023015152A MX2023015152A MX2023015152A MX 2023015152 A MX2023015152 A MX 2023015152A MX 2023015152 A MX2023015152 A MX 2023015152A MX 2023015152 A MX2023015152 A MX 2023015152A MX 2023015152 A MX2023015152 A MX 2023015152A
Authority
MX
Mexico
Prior art keywords
antibodies
canine
anti canine
relates
compositions
Prior art date
Application number
MX2023015152A
Other languages
English (en)
Inventor
Allan Bradley
Daniel Bolland
Juexuan Wang
Ruhcha Vijay Sutavani
Original Assignee
Petmedix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2108677.2A external-priority patent/GB202108677D0/en
Priority claimed from GBGB2202635.5A external-priority patent/GB202202635D0/en
Application filed by Petmedix Ltd filed Critical Petmedix Ltd
Publication of MX2023015152A publication Critical patent/MX2023015152A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La divulgación se refiere a anticuerpos y porciones de unión al antígeno de estos que se unen a CD20 canino. La presente divulgación también se refiere a composiciones y métodos para el tratamiento de una afección mediada por linfocitos B en un sujeto canino.
MX2023015152A 2021-06-17 2022-06-17 Anticuerpos anti-cd20 canino. MX2023015152A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2108677.2A GB202108677D0 (en) 2021-06-17 2021-06-17 Therapeutic antibodies
GBGB2202635.5A GB202202635D0 (en) 2022-02-25 2022-02-25 Therapeutic antibodies
PCT/GB2022/051559 WO2022263864A1 (en) 2021-06-17 2022-06-17 Anti canine cd20 antibodies

Publications (1)

Publication Number Publication Date
MX2023015152A true MX2023015152A (es) 2024-05-31

Family

ID=82482910

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023015152A MX2023015152A (es) 2021-06-17 2022-06-17 Anticuerpos anti-cd20 canino.

Country Status (10)

Country Link
US (1) US20250297026A1 (es)
EP (1) EP4355782A1 (es)
JP (1) JP2024526122A (es)
KR (1) KR20240021959A (es)
AU (1) AU2022294198A1 (es)
BR (1) BR112023026592A2 (es)
CA (1) CA3224517A1 (es)
CO (1) CO2024000339A2 (es)
MX (1) MX2023015152A (es)
WO (1) WO2022263864A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025121944A1 (ko) * 2023-12-08 2025-06-12 주식회사 박셀바이오 개 cd20을 표적으로 하는 항체, 키메라 항원 수용체 및 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
WO2011057188A1 (en) * 2009-11-06 2011-05-12 Idexx Laboratories, Inc. Canine anti-cd20 antibodies
US20140294819A1 (en) * 2011-10-13 2014-10-02 Nvip Pty Ltd Canine/feline cd20 binding epitope and compositions for binding thereto
CA2853637C (en) * 2011-10-26 2023-04-04 Novartis Ag Anti-canine cd20 monoclonal antibodies and methods of use
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
JP6661019B2 (ja) * 2016-02-18 2020-03-11 エランコ・ユーエス・インコーポレイテッドＥｌａｎｃｏ ＵＳ Ｉｎｃ． イヌ抗ｃｄ２０抗体
GB2561352B (en) 2017-04-10 2023-01-18 Genome Res Ltd Animal models and therapeutic molecules
GB2578867A (en) 2018-10-09 2020-06-03 Genome Res Ltd Animal models and therapeutic molecules

Also Published As

Publication number Publication date
CA3224517A1 (en) 2022-12-22
KR20240021959A (ko) 2024-02-19
AU2022294198A1 (en) 2023-12-21
EP4355782A1 (en) 2024-04-24
US20250297026A1 (en) 2025-09-25
WO2022263864A1 (en) 2022-12-22
BR112023026592A2 (pt) 2024-03-05
JP2024526122A (ja) 2024-07-17
CO2024000339A2 (es) 2024-05-10

Similar Documents

Publication Publication Date Title
CR20200467A (es) Agentes anticuerpos anti-cd25
MX2020008446A (es) Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4.
MX2024013016A (es) Anticuerpos anti-pd1 para usarse en el tratamiento del cancer
EA201992526A1 (ru) Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения
EA201891428A1 (ru) Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
UA117901C2 (uk) Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
MX2025008444A (es) Uso de un anticuerpo anti-pd-1 y un anticuerpo anti-cd3 x muc16 biespecifico para el tratamiento de un tumor que expresa muc16
ZA201803079B (en) Anti-dr5 antibodies and methods of use thereof
EA201691858A1 (ru) Композиции антител для лечения опухолей
EA201891495A1 (ru) Биспецифические анти-cd20/анти-cd3 антитела для лечения острого лимфобластного лейкоза
MY153893A (en) Antibodies against human il17 and uses thereof
MX353931B (es) Anticuerpos que se unen a ox40 y sus usos.
NZ759835A (en) Cd38 modulating antibody
EP4276108A3 (en) Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
EA202192413A1 (ru) АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ
ZA201806397B (en) Humanized anti clever-1 antibodies and their use
WO2021203030A3 (en) Methods of use of anti-trem2 antibodies
MX2021000933A (es) Anticuerpos anti-siglec-5 y métodos para su uso.
MX2023015152A (es) Anticuerpos anti-cd20 canino.
MX2021003756A (es) Composiciones farmaceuticas que comprenden anticuerpos anti cumulo de diferenciacion 37 (cd37) biespecificos.
EA202092595A1 (ru) Антитела к siglec-7 и способы их применения
PH12020551451A1 (en) Anti-cd25 for tumour specific cell depletion
PH12018501674A1 (en) Anti-citrullinated hla polypeptide antibodies and uses thereof
MX2022003191A (es) Terapias de combinacion con anticuerpos entpd2 y cd73.